

LIFE SAVING DRUGS PROGRAM EXPERT PANEL

16th MEETING: 20 October 2023

AGENDA

1. Standing business

- 1.1. Welcome, apologies and Conflicts of Interest
- 1.2. Update on actions from previous meetings
- 1.3. Correspondence
- 1.4. Report from the Secretariat

2. Reviews of existing LSDP medicines

- 2.1. Process for 24 month reviews
- 2.2. Update on upcoming 24 month reviews

3. Applications for new LSDP medicines

- 3.1. Olipudase alfa (Xenpozyme[®]) – for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B

4. Other business

- 4.1. Expert Panel input to HTA Policy and Methods Review